EUCTR2018-001267-22-NL
Active, not recruiting
Phase 1
F18-PSMA-1007 PET for early biochemical recurrence of prostate cancer, comparison with 18F-Fluciclovine.
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Radboud University Medical Center
- Enrollment
- 50
- Status
- Active, not recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •In order to be eligible to participate in this study, a subject must meet all of the following criteria:
- •\- Males \= 18 years
- •\- Histologically proven adenocarcinoma of the prostate
- •\- Prior local treatment with curative intent
- •\- Biochemical recurrence with PSA\-levels of 0\.2\-5\.0 ug/L
- •\- PSA level determined \<8 weeks before study participation
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range 15
Exclusion Criteria
- •A patient will be excluded from participation in the trial if one or more of the following criteria are met:
- •\- Contra\-indications for PET\-CT: claustrophobia or inability to lay still for the duration of the exam.
- •\- Other cancer \< 2 years prior to biochemical recurrence
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
F18-PSMA-1007 PET for early biochemical recurrence of prostate cancer, comparison with 18F-Fluciclovine.Prostate carcinomaadenocarcinoma of the prostate10038597NL-OMON48761Radboud Universitair Medisch Centrum50
Unknown
Not Applicable
F18-PSMA-1007 PET for Early Biochemical Recurrence of Prostate CancerProstate Cancer RecurrentNCT04239742Radboud University Medical Center50
Completed
Not Applicable
Model of Predicting Biochemical Recurrence After Radical Prostate Cancer Based on Pre-treatment PSMA PET / MR Image FeaturesProstate CancerNCT06604377Ruijin Hospital203
Completed
Phase 3
Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate CancerProstate CancerProstate Cancer RecurrentNCT04742361ABX advanced biochemical compounds GmbH136
Active, not recruiting
Phase 1
18F-fluoride PET for Early Non-invasive Assessment of Cortical Bone Formation - Non-invasive Assessment of Cortical Bone Formation - Version 1EUCTR2009-016523-61-GBKing’s College London30